Should You Continue to Hold TMO Stock in Your Portfolio?

Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.

Zacks Investment Research • Sep 4, 2026

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific today announced the launch of the Thermo Scientific™ Multiskan™ Ease Absorbance Microplate Reader, designed to support protein quantification, enzyme-linked immunosorbent assays (ELISAs), cell viability studies, microbial growth monitoring and other routine laboratory applications with simplified operation and dependable performance. Laboratories performing absorbance-based analysis are under increasing pressure to generate reliable data.

Business Wire • Sep 2, 2026

Why Moderna's Cancer Vaccine Matters to Investors

Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.

ETF Trends • Sep 2, 2026

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Thermo Fisher's EMPAD G2 detector enhances 4D STEM imaging speed, sensitivity and workflow integration, strengthening its Analytical Instruments portfolio.

Zacks Investment Research • Sep 1, 2026

Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman and chief executive officer, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026 at 9:15 a.m. (ET).You can access the live webcast of the presentation via the Investors section of our website, www.thermofisher.com.About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leade.

Business Wire • Sep 1, 2026

Thermo Fisher Scientific Introduces the Thermo Scientific™ EMPAD™ G2 Electron Detector to Advance Materials Research

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Thermo Scientific™ EMPAD™ G2 detector, a new detector designed to help researchers see and understand materials in unprecedented detail. EMPAD G2 enables high-speed four-dimensional scanning transmission electron microscopy (4D STEM), an advanced form of electron microscopy that captures far more information about a material than a standard image, helping researchers better.

Business Wire • Aug 27, 2026

Delta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Delta Air Lines, Inc. (NYSE:DAL).

Benzinga • Aug 26, 2026

Thermo Fisher Scientific Launches First Orbitrap Mass Spectrometers for Isotope Ratio Analysis, Enabling More Labs to Decode the Story Behind a Sample

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today introduced the Thermo Scientific™ Orbitrap™ Isora™ Mass Spectrometer and Orbitrap Isora Pro Mass Spectrometer, the company's first Orbitrap instruments with a dedicated isotope ratio analysis mode. Together with the Thermo Scientific™ Vanquish™ Duo UHPLC System and new Isotope Discoverer™ Software, the instruments form an integrated workflow designed to make molecular-level isotope ratio analys.

Business Wire • Aug 25, 2026

Thermo Fisher Scientific: Biopharma Recovery And Share Gains Support The Upside

Thermo Fisher Scientific is rated a Buy, supported by accelerating organic growth and improving Pharma and Biotech end markets. TMO's recent acquisitions of Clario and Solventum's Filtration and Separation business expand capabilities, enabling greater share of customer spending and revenue synergies. Q2 2026 results showed 10% revenue growth, 5% organic growth, and improved margins, with Pharma and Biotech driving mid-single-digit gains.

Seeking Alpha • Aug 16, 2026

Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist

LUXEMBOURG & NEW YORK & PARIS--(BUSINESS WIRE)--Astorg, a leading pan-European private equity firm, today announced the successful completion of its acquisition of the global microbiology business from Thermo Fisher Scientific. The business will now operate as an independent company under the leadership of Chief Executive Officer Dirk Bontridder and will launch under a new corporate brand later in 2026. The Microbiology business is a global provider of diagnostic consumables and equipment used.

Business Wire • Aug 12, 2026